ABBV monthly performance report
Monthly ABBV research: returns, drawdown, relative strength, seasonality, and key stats.
ABBV monthly report
—
Key takeaways
- AbbVie (ABBV) closed August 2026 at $246.20, down 1.89% for the month and +24.00% over the trailing 12 months.
- Year-to-date, ABBV is +7.75%, underperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +9.45% versus its 200-day moving average ($224.95), a bullish technical signal.
- Over the past three years, ABBV has underperformed the S&P 500 by −5.63%, with a relative strength index reading of 95.9.
- Win rate over the trailing 39 months stands at 59% — 23 positive months versus 16 negative months.
AbbVie ended August 2026 at $246.20, posting a monthly return of −1.89%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −4.94%.
The current quarter stands at −0.14% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +9.45% versus the 200-day moving average ($224.95).
Year-to-date, ABBV is +7.75% against SPY +12.89%, a gap of −5.13%. The stock is currently −7.95% below its 52-week high, with maximum 3-year drawdown at −21.46%.
| Period | ABBV | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.98% | −0.20% | +1.18% |
| 1 Week | −6.46% | +3.90% | −10.36% |
| 1 Month | −1.89% | +3.05% | −4.94% |
| 3 Months | +16.51% | +7.11% | +9.39% |
| 6 Months | +9.11% | +10.70% | −1.58% |
| YTD | +7.75% | +12.89% | −5.13% |
| 12 Months | +24.00% | +22.58% | +1.42% |
| 3 Years | +66.66% | +72.29% | −5.63% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +16.90% |
| #2 | Feb 2025 | +14.11% |
| #3 | Jul 2023 | +11.63% |
| #4 | Aug 2025 | +10.78% |
| #5 | Sep 2025 | +10.18% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2024 | −10.58% |
| #2 | Nov 2024 | −10.49% |
| #3 | Apr 2025 | −7.32% |
| #4 | Mar 2026 | −6.92% |
| #5 | Oct 2025 | −6.68% |
| Quarter | Return |
|---|---|
| Q2 2025 | −10.63% |
| Q3 2025 | +24.71% |
| Q4 2025 | −1.37% |
| Q1 2026 | −6.33% |
| Q2 2026 | +16.73% |
| Q3 2026 (QTD) | −0.14% |
| Year | Return |
|---|---|
| 2023 | −0.29% |
| 2024 | +15.41% |
| 2025 | +28.84% |
| 2026 | +9.18% |
| Metric | Value |
|---|---|
| 52-Week High | $267.47 (2026-07-29) |
| 52-Week Low | $191.00 (2026-04-29) |
| Current Price | $246.20 |
| 200-Day Moving Average | $224.95 |
| Price vs 200DMA | +9.45% |
| 3-Year Maximum Drawdown | −21.46% (2025-04-21) |
| Current Drawdown from 52W High | −7.95% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 95.9 |
| 3-Year Excess Return vs S&P 500 | −5.63% |
| RS Peak | 115.9 (Mar 2025) |
| RS Trough | 81.9 (May 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was ABBV's return for this report period?
ABBV returned −1.89% in the latest monthly window ending 2026-08-05.
Has ABBV outperformed SPY year to date?
YTD ABBV: +7.75% vs SPY: +12.89%.
What is ABBV's 12-month return?
+24.00% over the trailing 12 months.
Is ABBV above or below its 200-day moving average?
Price is +9.45% versus 200DMA ($224.95).
What is the maximum drawdown in the 3-year window?
−21.46% on 2025-04-21.